Intensity Therapeutics

Shelton – October 30, 2026 -- Intensity Therapeutics (Nasdaq: INTS) will report third-quarter 2026 financial results before the market opens on November 5, 2026, with management hosting a live webcast and conference call at 8:00 a.m. Eastern time to review the numbers and give a corporate update.

The quarter covers the period ended September 30, 2026. An archived webcast will be available for replay shortly after the call ends.

Phase 3 sarcoma trial is the late-stage anchor of the pipeline

The late-stage clinical biotech develops intratumoral cancer therapies. Its lead candidate, INT230-6, combines cisplatin and vinblastine sulfate with a penetration enhancer molecule called SHAO, which the company says disperses the drugs throughout tumors. The drug is injected directly into the tumor.